Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Accumulated Expenses (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Accumulated Expenses data on record, last reported at $40.6 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 16.97% year-over-year to $40.6 million; the TTM value through Sep 2025 reached $40.6 million, up 16.97%, while the annual FY2024 figure was $45.7 million, 89.69% up from the prior year.
  • Accumulated Expenses reached $40.6 million in Q3 2025 per VRDN's latest filing, up from $35.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $45.7 million in Q4 2024 and bottomed at $10.3 million in Q3 2021.
  • Average Accumulated Expenses over 5 years is $22.6 million, with a median of $19.0 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: surged 368.54% in 2021, then decreased 9.43% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $11.0 million in 2021, then surged by 70.87% to $18.8 million in 2022, then increased by 28.05% to $24.1 million in 2023, then soared by 89.69% to $45.7 million in 2024, then decreased by 11.15% to $40.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $40.6 million in Q3 2025, $35.3 million in Q2 2025, and $45.7 million in Q4 2024.